|
1
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:S6243–S6249. 2006. View Article : Google Scholar
|
|
2
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
5
|
Siclari VA, Guise TA and Chirgwin JM:
Molecular interactions between breast cancer cells and the bone
microenvironment drive skeletal metastases. Cancer Metastasis Rev.
25:621–633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fidler IJ and Poste G: The ‘seed and soil’
hypothesis revisited. Lancet Oncol. 9:8082008. View Article : Google Scholar
|
|
7
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boyce BF and Xing L: Functions of
RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem
Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda
H, Tsuda E, Higashio K, Miyata T and Kumegawa M: Osteoclastogenesis
inhibitory factor (OCIF) directly inhibits bone-resorbing activity
of isolated mature osteoclasts. Biochem Biophys Res Commun.
251:796–801. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yasuda H, Shima N, Nakagawa N, Mochizuki
SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et
al: Identity of osteoclastogenesis inhibitory factor (OCIF) and
osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits
osteoclastogenesis in vitro. Endocrinology. 139:1329–1337.
1998.PubMed/NCBI
|
|
11
|
Ibrahim T, Sacanna E, Gaudio M, Mercatali
L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, et al: Role
of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone
metastases in breast cancer patients. Clin Breast Cancer.
11:369–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mercatali L, Ibrahim T, Sacanna E, Flamini
E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, et al:
Bone metastases detection by circulating biomarkers: OPG and
RANK-L. Int J Oncol. 39:255–261. 2011.PubMed/NCBI
|
|
13
|
Van Poznak C, Cross SS, Saggese M, Hudis
C, Panageas KS, Norton L, Coleman RE and Holen I: Expression of
osteoprotegerin (OPG), TNF related apoptosis inducing ligand
(TRAIL), and receptor activator of nuclear factor kappaB ligand
(RANKL) in human breast tumours. J Clin Pathol. 59:56–63. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neville-Webbe HL, Cross NA, Eaton CL,
Nyambo R, Evans CA, Coleman RE and Holen I: Osteoprotegerin (OPG)
produced by bone marrow stromal cells protects breast cancer cells
from TRAIL-induced apoptosis. Breast Cancer Res Treat. 86:269–279.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Holen I, Cross SS, Neville-Webbe HL, Cross
NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman
RE and Eaton CL: Osteoprotegerin (OPG) expression by breast cancer
cells in vitro and breast tumours in vivo - a role in tumour cell
survival? Breast Cancer Res Treat. 92:207–215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nicolin V and Narducci P: Soluble TRAIL
could enhance bone destruction acting on Rank-ligand in
estrogen-independent human breast cancer cell line MDA-MB-231. Acta
Histochem. 112:189–192. 2010. View Article : Google Scholar
|
|
17
|
Michalopoulos G, Houck KA, Dolan ML and
Leutteke NC: Control of hepatocyte replication by two serum
factors. Cancer Res. 44:4414–4419. 1984.PubMed/NCBI
|
|
18
|
Nakamura T, Nawa K and Ichihara A: Partial
purification and characterization of hepatocyte growth factor from
serum of hepatectomized rats. Biochem Biophys Res Commun.
122:1450–1459. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Russell WE, McGowan JA and Bucher NL:
Biological properties of a hepatocyte growth factor from rat
platelets. J Cell Physiol. 119:193–197. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang WG, Martin TA, Parr C, Davies G,
Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor,
and their potential value in cancer therapies. Crit Rev Oncol
Hematol. 53:35–69. 2005. View Article : Google Scholar
|
|
21
|
Parikh RA, Wang P, Beumer JH, Chu E and
Appleman LJ: The potential roles of hepatocyte growth factor
(HGF)-MET pathway inhibitors in cancer treatment. Onco Targets
Ther. 7:969–983. 2014.PubMed/NCBI
|
|
22
|
Davies S and Jiang WG: ALCAM, activated
leukocyte cell adhesion molecule, influences the aggressive nature
of breast cancer cells, a potential connection to bone metastasis.
Anticancer Res. 30:1163–1168. 2010.PubMed/NCBI
|
|
23
|
Sanders AJ, Parr C, Mason MD and Jiang WG:
Suppression of hepatocyte growth factor activator inhibitor-1 leads
to a more aggressive phenotype of prostate cancer cells in vitro.
Int J Mol Med. 20:613–619. 2007.PubMed/NCBI
|
|
24
|
Yuan Z, Sanders AJ, Ye L, Wang Y and Jiang
WG: Knockdown of human antigen R reduces the growth and invasion of
breast cancer cells in vitro and affects expression of cyclin D1
and MMP-9. Oncol Rep. 26:237–245. 2011.PubMed/NCBI
|
|
25
|
Zuker M: Mfold web server for nucleic acid
folding and hybridization prediction. Nucleic Acids Res.
31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang WG, Hiscox S, Hallett MB, Horrobin
DF, Mansel RE and Puntis MC: Regulation of the expression of
E-cadherin on human cancer cells by gamma-linolenic acid (GLA).
Cancer Res. 55:5043–5048. 1995.PubMed/NCBI
|
|
27
|
Jiang WG, Hiscox S, Singhrao SK, Nakamura
T, Puntis MC and Hallett MB: Inhibition of HGF/SF-induced membrane
ruffling and cell motility by transient elevation of cytosolic free
Ca2+. Exp Cell Res. 220:424–433. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosen EM, Carley W and Goldberg ID:
Scatter factor regulates vascular endothelial cell motility. Cancer
Invest. 8:647–650. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Albini A, Iwamoto Y, Kleinman HK, Martin
GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay
for quantitating the invasive potential of tumor cells. Cancer Res.
47:3239–3245. 1987.PubMed/NCBI
|
|
30
|
Parish CR, Jakobsen KB and Coombe DR: A
basement-membrane permeability assay which correlates with the
metastatic potential of tumour cells. Int J Cancer. 52:378–383.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Owen S, Ye L, Sanders AJ, Mason MD and
Jiang WG: Expression profile of receptor activator of nuclear-κB
(RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast
cancer. Anticancer Res. 33:199–206. 2013.
|
|
32
|
Raghav KP, Wang W, Liu S, Chavez-MacGregor
M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein
GR Jr and Gonzalez-Angulo AM: cMET and phospho-cMET protein levels
in breast cancers and survival outcomes. Clin Cancer Res.
18:2269–2277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zinonos I, Luo KW, Labrinidis A, Liapis V,
Hay S, Panagopoulos V, Denichilo M, Ko CH, Yue GG, Lau CB, et al:
Pharmacologic inhibition of bone resorption prevents cancer-induced
osteolysis but enhances soft tissue metastasis in a mouse model of
osteolytic breast cancer. Int J Oncol. 45:532–540. 2014.PubMed/NCBI
|
|
34
|
Weichhaus M, Segaran P, Renaud A, Geerts D
and Connelly L: Osteoprotegerin expression in triple-negative
breast cancer cells promotes metastasis. Cancer Med. 3:1112–1125.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Body JJ, Greipp P, Coleman RE, Facon T,
Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams
CD, et al: A phase I study of AMGN-0007, a recombinant
osteoprotegerin construct, in patients with multiple myeloma or
breast carcinoma related bone metastases. Cancer. 97(Suppl):
887–892. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chanda D, Isayeva T, Kumar S, Siegal GP,
Szafran AA, Zinn KR, Reddy VV and Ponnazhagan S: Systemic
osteoprotegerin gene therapy restores tumor-induced bone loss in a
therapeutic model of breast cancer bone metastasis. Mol Ther.
16:871–878. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blake ML, Tometsko M, Miller R, Jones JC
and Dougall WC: RANK expression on breast cancer cells promotes
skeletal metastasis. Clin Exp Metastasis. 31:233–245. 2014.
View Article : Google Scholar
|
|
38
|
Casimiro S, Mohammad KS, Pires R,
Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A,
Guise TA, et al: RANKL/RANK/MMP-1 molecular triad contributes to
the metastatic phenotype of breast and prostate cancer cells in
vitro. PLoS One. 8:e631532013. View Article : Google Scholar : PubMed/NCBI
|
